Exploratory human trials of rectal microbicides

直肠杀菌剂的探索性人体试验

基本信息

  • 批准号:
    7979345
  • 负责人:
  • 金额:
    $ 12.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-18 至 2010-07-31
  • 项目状态:
    已结题

项目摘要

This proposal will address the critical issues pertinent to the development of reverse transcriptase (RT) antiretroviral rectal microbicides The proposed studies will use the RT inhibitor UC-781 as a candidate rectal microbicide and Biosyn Inc., will be the private sector leader of the project. The first aim of this proposal will be to define the optimal preclinical safety assessment of an RT rectal microbicide with the necessary Investigational New Drug Application (IND) studies, followed by studies in HIV seronegative subjects with subsequent evaluation in HIV seropositive subjects. Although the studies proposed in this project focus on the RT class of microbicide it is anticipated that the methodological approaches developed in this proposal could be used to evaluate other classes of microbicide for safety and preliminary efficacy. There are four specific goals in Aim 1: (1) To conduct the necessary preclinical animal studies, to file an IND, to allow human studies involving rectal administration of UC-781 gel, (2) To determine the sensitivity and specificity of a broad range of immunological, molecular and histopathological parameters in assessing potential microbicide toxicity, (3) To evaluate the intestinal explant / infection system as a means of generating early ex vivo/in vitro evidence of rectal microbicide efficacy in resisting HIV infection, and (4) To characterize the effect of anal coital activity on the distribution and bioavailabilty of UC-781 gel. The second aim of the study is to characterize the virological sequelae of rectal administration of UC-781 gel in subjects with HIV-1 infection. More specifically, studies will be conducted to determine the kinetic changes in plasma, mucosal, and rectal secretion HIV-1 viral load after rectal administration ofUC-781 gel. In addition, baseline and post treatment mucosal and plasma viral isolates will be genotyped to determine whether exposure to UC-781 gel is associated with evolution of viral mutations and whether these changes are restricted to the rectal mucosal compartment or can be detected in the plasma compartment. Completion of these studies will provide the necessary data to optimize the future conduct of rectal microbicide Phasel trials, provide specific information on the virological responses to RT microbicides in HIV positive subjects, and compliment the preclinical/discovery phase of rectal microbicide drug development begun in Project 1 of this U-19 Grant.
这项建议将解决与逆转录酶(RT)发展相关的关键问题 抗逆转录病毒直肠杀菌剂拟议的研究将使用RT抑制剂UC-781作为候选直肠 杀菌剂和Biosyn Inc.将成为该项目的私营部门领导者。 该提案的第一个目标是确定直肠放射治疗的最佳临床前安全性评估。 杀微生物剂和必要的新药物应用研究(IND),随后是艾滋病毒研究 血清阴性的受试者和HIV血清阳性受试者的后续评估。虽然本项目建议的研究侧重于RT类杀微生物剂,但预计本建议中开发的方法学方法也可用于评估其他类杀菌剂的安全性和初步药效。目标1确定了四个具体目标:(1)进行必要的临床前动物研究,提交IND文件,以便进行涉及直肠给药的人体试验;(2)确定评估潜在杀菌剂毒性的各种免疫学、分子和组织病理学参数的敏感性和特异性;(3)评估肠道外植体/感染系统,作为产生早期体外/体外证据的手段,证明直肠杀菌剂在抵抗艾滋病毒感染方面的有效性;以及(4)表征肛交活动对UC-781凝胶分布和生物利用度的影响。 这项研究的第二个目的是描述直肠给药UC-781凝胶的病毒学后遗症。 HIV-1感染的受试者。更具体地说,将进行研究,以确定在直肠给药UC-781凝胶后血浆、粘膜和直肠分泌物中HIV-1病毒载量的动态变化。此外,基线和治疗后的粘膜和血浆病毒分离株将进行基因分型,以确定暴露在UC-781凝胶中是否与病毒突变的演变有关,以及这些变化是否仅限于直肠粘膜间隔或可以在血浆间隔检测到。这些研究的完成将提供必要的数据,以优化未来进行的直肠杀微生物剂Phasel试验,提供关于HIV阳性受试者对RT杀微生物剂的病毒学反应的具体信息,并补充U-19拨款项目1中开始的直肠杀微生物剂药物开发的临床前/发现阶段。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter A Anton其他文献

The Other Compartment: Challenges and Progress in Rectal Microbicide Development
  • DOI:
    10.1186/1742-4690-2-s1-s89
  • 发表时间:
    2005-12-08
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    Peter A Anton
  • 通讯作者:
    Peter A Anton

Peter A Anton的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter A Anton', 18)}}的其他基金

Topical Microbicides: Targeted Intracellular Delivery
局部杀菌剂:靶向细胞内递送
  • 批准号:
    8810224
  • 财政年份:
    2014
  • 资助金额:
    $ 12.2万
  • 项目类别:
Topical Microbicides: Targeted Intracellular Delivery
局部杀菌剂:靶向细胞内递送
  • 批准号:
    8711813
  • 财政年份:
    2014
  • 资助金额:
    $ 12.2万
  • 项目类别:
Mechanistic Studies of HIV-exposed Seronegative Individuals
HIV 血清阴性个体的机制研究
  • 批准号:
    8503631
  • 财政年份:
    2012
  • 资助金额:
    $ 12.2万
  • 项目类别:
Data management and biostatistics
数据管理和生物统计学
  • 批准号:
    7979343
  • 财政年份:
    2009
  • 资助金额:
    $ 12.2万
  • 项目类别:
Administrative
行政的
  • 批准号:
    7979338
  • 财政年份:
    2009
  • 资助金额:
    $ 12.2万
  • 项目类别:
Regulatory compliance and human subjects safety
法规遵从性和人体受试者安全
  • 批准号:
    7979340
  • 财政年份:
    2009
  • 资助金额:
    $ 12.2万
  • 项目类别:
Mucosal Immunology Core
粘膜免疫学核心
  • 批准号:
    7480739
  • 财政年份:
    2008
  • 资助金额:
    $ 12.2万
  • 项目类别:
Core A - Administrative
核心 A - 行政
  • 批准号:
    7127921
  • 财政年份:
    2006
  • 资助金额:
    $ 12.2万
  • 项目类别:
Microbicide Development Program (MDP)
杀菌剂开发计划 (MDP)
  • 批准号:
    7278576
  • 财政年份:
    2004
  • 资助金额:
    $ 12.2万
  • 项目类别:
Microbicide Development Program (MDP)
杀菌剂开发计划 (MDP)
  • 批准号:
    7107173
  • 财政年份:
    2004
  • 资助金额:
    $ 12.2万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.2万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了